Compare SYRE & MRCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYRE | MRCY |
|---|---|---|
| Founded | 2013 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.1B |
| IPO Year | 2015 | 1997 |
| Metric | SYRE | MRCY |
|---|---|---|
| Price | $71.71 | $80.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $85.08 | $80.00 |
| AVG Volume (30 Days) | ★ 1.3M | 395.1K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.69 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $912,020,000.00 |
| Revenue This Year | N/A | $6.59 |
| Revenue Next Year | N/A | $9.56 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.19 |
| 52 Week Low | $12.29 | $44.01 |
| 52 Week High | $76.00 | $103.81 |
| Indicator | SYRE | MRCY |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 50.67 |
| Support Level | $30.39 | $71.79 |
| Resistance Level | $74.92 | $86.69 |
| Average True Range (ATR) | 4.18 | 3.42 |
| MACD | -0.78 | -0.10 |
| Stochastic Oscillator | 43.70 | 44.57 |
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.